Upgrade to SI Premium - Free Trial

Pre-Open Movers 11/18: (CRMD) (BA) (SPR) Higher; (PAYS) (PII) (LOW) Lower (more...)

November 18, 2020 9:27 AM

Today's Pre-Open Stock Movers

Paysign, Inc. (NASDAQ: PAYS) 20.2% LOWER; reported Q3 EPS of ($0.12), $0.14 worse than the analyst estimate of $0.02.

Newpark Resources (NYSE: NR) 16.4% HIGHER; CEO, Paul Howes, disclosed the purchase of 57,500 shares from 11/13-11/16 at prices from $1.15-$1.30.

CorMedix Inc. (NYSE American: CRMD) 16% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has decided to cancel the Antimicrobial Drug Advisory Committee meeting tentatively scheduled for January 14, 2021 to discuss the New Drug Application (NDA) for Defencath®. When the FDA accepted for filing the Companys submitted NDA and granted priority review, it set a Prescription Drug User Fee Act (PDUFA) date of February 28, 2021 for the completion of its review for approval of the NDA. The Agency noted that it was planning to hold an advisory committee meeting to discuss the application for Defencath to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI) and that it had not identified any potential review issues at that time. CorMedix has been notified that based on the Agencys ongoing dialogue with the Company, discussion at an advisory committee is not needed, and it will continue to work on the application with CorMedix during the remainder of the review cycle.

Varex Imaging Corporation (NASDAQ: VREX) 7.4% HIGHER; reported Q4 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $170 million versus the consensus estimate of $162.1 million. Varex Imaging Corporation sees Q1 2021 EPS of ($0.15)-$0.10, versus the consensus of $0.02. Varex Imaging Corporation sees Q1 2021 revenue of $160-180 million, versus the consensus of $173.73 million.

Polaris Inc. (NYSE: PII) 7.3% LOWER; announced that Chairman and CEO Scott Wine will leave Polaris to assume the CEO role at CNH Industrial (NYSE: CNHI). Wine will remain in his current role at Polaris through the end of the year as the Board executes its succession plans. Transition plans will be announced at a later date.

Boeing (NYSE: BA) 7% HIGHER; 737 Max Wins Approval From U.S. FAA to Resume Flight

Lowe's Cos. (NYSE: LOW) 6.4% LOWER; reported Q3 EPS of $1.98, $0.01 worse than the analyst estimate of $1.99. Revenue for the quarter came in at $22.3 billion versus the consensus estimate of $21.25 billion. Lowe's Cos. sees Q4 2020 EPS of $1.10-$1.20, versus the consensus of $1.16.

Spirit AeroSystems Holdings, Inc. (NYSE: SPR) 6% HIGHER; 737 Max Wins Approval From U.S. FAA to Resume Flight

GoodRx Holdings Inc. (NASDAQ: GDRX) 5.9% LOWER; JPMorgan downgraded from Neutral to Underweight with a price target of $29.00 (from $59.00).

BioNTech SE (NASDAQ: BNTX) 5.6% HIGHER; BNT162b2, a Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) is 95% effective against the virus, according to the final efficacy analysis released this morning.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) 4.8% LOWER; commenced an underwritten public offering of 40,000,000 ordinary shares of the Company. The Company expects to use the net proceeds from the Offering for general corporate purposes.

TechnipFMC (NYSE: FTI) 4% HIGHER; has received a Notice to Proceed for a major(1) Engineering, Procurement, and Construction (EPC) contract by Sempra LNG and Infraestructura Energética Nova, S.A.B. de C.V. (IEnova) at their Energía Costa Azul (ECA) liquefied natural gas (LNG) facility in Baja California, Mexico. The project will add a natural gas liquefaction facility with nameplate capacity of 3.25 Mtpa(2) to the existing regasification terminal using a compact and high efficiency mid-scale LNG design.

La-Z-Boy (NYSE: LZB) 3.8% HIGHER; reported Q2 EPS of $0.82, $0.32 better than the analyst estimate of $0.50. Revenue for the quarter came in at $459.1 million versus the consensus estimate of $433.73 million.

Pfizer (NYSE: PFE) 2.6% HIGHER; BNT162b2, a Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) is 95% effective against the virus, according to the final efficacy analysis released this morning.

NIO Inc. (NYSE: NIO) 1.8% LOWER; reported Q3 EPS of ($0.12), $0.05 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $666.6 million versus the consensus estimate of $655.28 million. NIO Inc. sees Q4 2020 revenue of $921.8-947.9 million, versus the consensus of $805.66 million.

Categories

Special Reports